A Phase 2 interventional study of Abatacept and Placebo in Psoriatic Arthritis, sponsored by Bristol-Myers Squibb. Terminated at 44 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-08-01.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb — 1 open to participants now, 3 under way, 3 of them phase 3. Arthritis, Psoriatic · Bristol-Myers Squibb.
Among the 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb, this one is the only one that started in 2007, is one of 2 in phase 2, and was the 1st registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.
Browse Arthritis, Psoriatic studies →1 of the 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb is open now. Recruiting first, the newest first:
Bristol-Myers Squibb
Ages 4–75
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 191 is above the median of 145 across 336 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 203 across the 9 interventional studies, 38,396 across the 3 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Arthritis, Psoriatic by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine an optimal abatacept dosing regimen for the treatment of active arthritis due to psoriatic arthritis in patients who have had a prior inadequate response to disease-modifying antirheumatic drugs, including methotrexate and tumor necrosis factor alpha-blockade compounds.
Key Inclusion Criteria:
Key Exclusion Criteria:
Long-term period participants: Must have met eligibility criteria for short-term period and completed short-term (24-week) period of the study
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Abatacept (30 mg/kg) was administered as intravenous (iv) infusion over approximately 30 minutes on Days 1 and 15, followed by 10 mg/kg (fixed dose) abatacept infusion on Day 29 and every 28 days thereafter up to and including Day 141. The dose was calculated based on screening visit weight of participants for dosing on Days 1 and 15 followed by fixed dosing as per rheumatoid arthritis label (participants weighing \<60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \>100 kg received 1000 mg) thereafter.
Drug: Abatacept
Abatacept (10 mg/kg) was administered as iv infusion over approximately 30 minutes on Days 1, 15, and 29 and every 28 days thereafter up to and including Day 141 in the double-blind period and continued for next 18 months in the open-label period till Day 729. All participants received a dose based on their screening visit weight as per rheumatoid arthritis label (participants weighing \<60 kg received 500 mg, participants weighing 60 to 100 kg received 750 mg, and participants weighing \>100 kg received 1000 mg).
Drug: Abatacept
Abatacept (3 mg/kg) was administered as iv infusion over approximately 30 minutes on Days 1, 15, and 29 and every 28 days thereafter up to and including Day 141. The dose was calculated based on screening visit weight of participants.
Drug: Abatacept
Placebo solution (5% dextrose in water for injection, 0.9% sodium chloride injection) by iv infusion was administered on Days 1, 15, and 29 and every 28 days thereafter till Day 141.
Drug: Placebo
Solution, intravenous, monthly, short-term = 24 weeks (6 months)
Also known as: Orencia, BMS-188667
Solution, intravenous, placebo (double dummy), monthly, short-term = 24 weeks (6 months)
Long-term Period: Number of Participants With Death As Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Drug-related AEs, AEs Leading to Discontinuation, and AEs of Interest
Presp=prespecified; acute= ≤1 hour after start of infusion; periinfusional= ≤24 hours after start of infusion. AE=any new unfavorable symptom or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=an unfavorable medical event that at any dose results in death, significant disability, drug dependency/abuse, hospitalization or prolonged hospitalization; is life-threatening, an important medical event, or a congenital anomaly/birth defect. Drug-related=possibly, probably, or certainly related and of unknown relationship to study drug.
Time frame: From Day 169 to Day 729
Short-term Period: Number of Participants With ACR 20 Response at Day 169
An ACR 20 responder was a participant who had a reduction of 20% or more from baseline in scores for both tender and swollen joints and had a reduction from baseline of 20% or more in 3 out of the following 5 assessments: participant's assessment of disease activity, participant's global assessment of disease activity, investigator's global assessment of disease activity, participant's assessment of physical function by HAQ-DI, and Disease Activity Score 28-C reactive protein.
Time frame: At Day 169 from Baseline
Long-term Period: Percentage of Participants Achieving American College of Rheumatology (ACR) 20, ACR 50, ACR 70, ACR 90 Responses at Days 365 and 729
An ACR 20 (50, 70, 90) responder was a participant whose counts for both tender and swollen joints was reduced by 20% (50%, 70%, 90%, respectively) or more from baseline and who had a reduction of 20% (50%, 70%, 90%, respectively) or more from baseline in 3 of the following assessments: participant's assessment of disease activity, participant's global assessment of disease activity, Investigators Global Response, participant's assessment of physical function by Health Assessment Questionnaire Disability Index, and Disease Activity Score 28 based on C-reactive protein.
Time frame: At Days 365 and 729 from Baseline
Long-term Period: Number of Participants With an Investigators Global Assessment (IGA) Score of Clear or Almost Clear at Days 365 and 729
IGA score indicates lesion induration, scaling, and erythema: 0=clear (no signs of plaque psoriasis except for residual discoloration); 1=almost clear (just perceptible erythema, no induration to very slightly elevated above normal skin levels, limited amount of very fine scaling); 2=mild disease (mild erythema, mild induration, mainly fine scaling predominates); 3=moderate disease (moderate erythema \[most plaques are red\], moderate induration and/or coarse scale predominates); 4=severe (severe erythema, marked to very marked elevation of lesions, coarse thick scale predominates).
Time frame: From Day 169 to Days 365 and 729
Long-term Period: Mean Percentage of Change From Baseline in Target Lesion Score at Days 365 and 729
Target lesion score is a measurement of the degree of erythema, induration, and scale of a psoriatic lesion, at least 2 cm in diameter, selected as a target for response throughout the study period. The scores assigned were 0=clear, 1=almost clear, 2=mild clear, 3=moderate disease, 4=severe. Percent improvement from baseline was computed using the ratio of improvement from baseline to the baseline value.
Time frame: From Baseline to Days 365 and 729
Long-term Period: Mean Change From Baseline in the Short-form 36 (SF-36), Version 2, Domain and Component Scores at Days 365 and 729
PCS=physical component score; MCS=mental component score. The SF-36 is a 36-item instrument with physical and mental components and covers quality of life (QoL) domains: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health. Responses are used to derive physical and mental component summary scores, ranging from 0 to 100, with higher scores indicating better QoL. Mean change from baseline=postbaseline value-baseline value; a higher value signifies improvement.
Time frame: At Days 365 and 729 from baseline
Long-term Period: Number of Participants Achieving A Reduction of At Least 0.3 Unit From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Days 365 and 729
Per the HAQ-DI, participants assessed their own ability to perform the following tasks: dress/groom, arise, eat, walk, reach, grip, maintain hygiene, and maintain daily activity over a period by marking their responses on a questionnaire. Scoring of the HAQ-DI: 0=without any difficulty; 1=with some difficulty; 2=with much difficulty); and 3=unable to do. Greater score=greater disability. Responders with a \>= 0.3 unit decrease in index scores from baseline to days 365 and 729 were considered to be improved.
Time frame: Days 365 and 729 from baseline
Short-term Period: Number of Participants With Marked Abnormalities in Hematology
LLN=lower limit of normal; ULN=upper limit of normal; pre-Rx=pretreatment. Marked abnormalities are laboratory measurements marked as abnormal, per predefined study criteria, at any study time point. Criteria: Hemoglobin \>3 g/dL decrease from pre-Rx value; hematocrit \<0.75\*pre-Rx value; erythrocytes \<0.75\*pre-Rx value; platelets \<0.67\*LLN (or, if pre-Rx value \<LLN, \<0.5\*pre-Rx value and \<100000/mm\^3) or \>1.5\*ULN.
Time frame: From Baseline to Day 169
Short-term Period: Number of Participants With Marked Abnormalities in Hematology (Continued)
LLN=lower limit of normal; ULN=upper limit of normal; pre-Rx=pretreatment. Laboratory measurements are marked as abnormal per predefined study criteria, at any study time point. Criteria for the data presented. Leukocytes \<0.75\*LLN or \>1.25\*ULN (or, if pre-Rx value \<LLN, \<0.8\*pre-Rx or \>ULN. If pre-Rx value \>ULN, \>1.2\*pre-Rx or \<LLN); neutrophils+bands (absolute) \<1.00\*10\^3 c/uL; lymphocytes (absolute) \<0.75\*10\^3 c/uL or \>7.50\*10\^3 c/uL; monocytes (absolute) \>2000/mm\^3; basophils (absolute) \>0.40\*10\^3 c/uL; eosinophils (absolute) \>0.75\*10\^3 c/uL.
Time frame: From Baseline to Day 169
Short-term Period: Number of Participants With Marked Abnormalities in Serum Chemistry
ULN=upper limit of normal; pre-Rx=pretreatment. Marked abnormality criteria: Alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT) \>2\*ULN (if pre-Rx \>ULN, \>3\*pre-Rx); aspartate aminotransferase (AST), alanine transaminase (ALT) \>3\*ULN (if pre-Rx \>ULN, \>4\*pre-Rx); bilirubin (total) \>2\*ULN (if pre-Rx \>ULN, \>4\*pre-Rx); blood urea nitrogen (BUN) \>2\*pre-Rx; creatinine \>1.5\*pre-Rx.
Time frame: Baseline to Day 169
Short-term Period: Number of Participants With Marked Abnormalities in Serum Chemistry (Continued)
LLN=lower limit of normal; ULN=upper limit of normal; pre-Rx=pretreatment. Marked abnormality criteria: Sodium \<0.95\*LLN or \>1.05\*ULN (if pre-Rx\<LLN, \<0.95\*pre-Rx or \>ULN. If pre-Rx \>ULN,\>1.05\* pre-Rx or \<LLN); potassium, chloride \<0.9\*LLN or \>1.1\*ULN (if pre-Rx \<LLN, \<0.9\*pre-Rx or \>ULN. If pre-Rx \>ULN, \>1.1\*pre-Rx or \<LLN); calcium \<0.8\*LLN or \>1.2\*ULN (if pre-Rx \<LLN,\<0.75\* pre-Rx or \>ULN. If pre-Rx \>ULN, \>1.25\* pre-Rx or \<LLN); phosphorous \<0.75\*LLN or \>1.25\*ULN (if pre-Rx \<LLN, \<0.67\*pre-Rx or \>ULN. If pre-Rx \>ULN, \>1.33\*pre-Rx or \<LLN.
Time frame: Baseline to Day 169
Short-term Period: Number of Participants With Marked Abnormalities in Serum Chemistry (Continued)
LLN=lower limit of normal; ULN=upper limit of normal; pre-Rx=pretreatment. Marked abnormality criteria: Glucose \<65 or \>220 mg/dL; glucose (fasting)\<0.8\*LLN or \>1.5\*ULN (if pre-Rx \<LLN, \<0.8\*pre-Rx or \>ULN. If pre-Rx \>ULN, t\>2.0\*pre-Rx or \<LLN). Protein (total) \<0.9\*LLN or \>1.1\*ULN (if pre-Rx \<LLN, \<0.9\*pre-Rx or \>ULN. If pre-Rx \>ULN, \>1.1\*pre-Rx or \<LLN). Albumin \<0.9\*LLN (if pre-Rx \<LLN, \<0.75\* pre-Rx). Uric acid \>1.5\*ULN; if pre-Rx \>ULN or \>2\*pre-Rx value.
Time frame: From Baseline to Day 169
Short-term Period: Number of Participants With Marked Abnormalities in Urinalysis
Pre-Rx=pretreatment. Criteria for marked abnormality: Protein, glucose, blood, leukocyte esterase, red blood cells (RBC), white blood cells (WBC) \>=2+ (or, if value \>=4, or if pre-Rx value=0 or 0.5, \>= 2\* or if pre-RX value =1, \>=3, or if pre-Rx =2 or 3, \>=4).
Time frame: From Baseline to Day 169
Short-term Period: Number of Participants Who Died and With SAEs, AEs, AEs Leading to Discontinuation, SAEs Leading to Discontinuation, Drug-related AEs, and Drug-related SAEs
An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Drug-related=possibly, probably, or certainly related to and of unknown relationship to study treatment.
Time frame: From Baseline to Day 169
Short-term Period: Number of Participants With an IGA Score of Clear or Almost Clear at Day 169
Score indicates lesion induration, scaling, and erythema: 0 = clear (no signs of plaque psoriasis except for residual discoloration); 1 = almost clear (just perceptible erythema, no induration to very slightly elevated above normal skin levels, limited amount of very fine scaling); 2 = mild disease (mild erythema, mild induration, mainly fine scaling predominates); 3 = moderate disease (moderate erythema \[most plaques are red\], moderate induration and/or coarse scale predominates); 4=severe (severe erythema, marked to very marked elevation of lesions, coarse thick scale predominates).
Time frame: At Day 169 from Baseline
Short-term Period: Mean Percentage of Change From Baseline in Target Lesion Score at Day 169
Target lesion score measures the degree of erythema, induration, and scale of a psoriatic lesion with a diameter of at least 2 cm, selected as a target for response throughout the study period. Scores: 0=clear, 1=almost clear, 2=mild clear, 3=moderate disease, 4=severe. Percent improvement from baseline was computed using the ratio of improvement from baseline to the baseline value.
Time frame: At Day 169 from Baseline
Short-term Period: Number of Participants With Positive Responses for Serum Levels of Abatacept-specific Antibodies (Anti-Abatacept-C)
Meso Scale Discovery electrochemiluminescence, a validated, sensitive immunoassay technique (anti-abatacept assay C) was used to measure serum levels of abatacept-specific antibodies against the whole molecule (both the CTLA4 and possibly immunoglobulin G portion \[anti-abatacept antibody\].
Time frame: From Baseline to Day 169
Short-term Period: Mean Change From Baseline in the Mental Component Summary Score as Measured by the Short-form 36 at Day 169
PCS=physical component score; MCS=mental component score. The Short-form 36 is a 36-item instrument with physical and mental components and covers quality of life (QoL) domains: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health. Responses are used to derive physical and mental component summary scores, ranging from 0 to 100, with higher scores indicating better QoL. Mean change from baseline=postbaseline value-baseline value; a higher value signifies improvement.
Time frame: At Day 169 from Baseline
Short-term Period: Mean Serum Concentrations of Abatacept
Abatacept was assayed using a validated enzyme linked immunosorbent assay method (ELISA). Serum concentration versus time data was analyzed in the descriptive pharmacokinetic (PK) analysis.
Time frame: Days 1, 15, 29, 57, 85, 113, 141, and 169
Short-term Period: Mean Serum Trough Concentrations (Cmin) of Abatacept
Abatacept was assayed using a validated ELISA method. Cmin of abatacept was obtained from concentration versus time data.
Time frame: Days 1, 15, 29, 57, 85, 113, 141, and 169
Short-term Period: Population Pharmacokinetic (POPPK) Analysis of the Pharmacokinetic (PK) Parameters
PK data: summaries of concentrations and concentration versus time plots were obtained. These data were to be used to develop a POPPK model using a nonlinear mixed-effects model. Prediction of PK data for each of the 3 abatacept treatment groups using POPPK methodology was not performed, because it would not provide any relevant information over the observed PK data.
Time frame: Days 1, 15, 29, 57, 85, 113, 141, and 169
Short-term Period: Mean Change From Baseline in Physical Component Summary Score as Measured by the Short-form 36 at Day 169
PCS=physical component score; MCS=mental component score. The Short-form 36 is a 36-item instrument with physical and mental components and covers quality of life (QoL) domains: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health. Responses are used to derive physical and mental component summary scores, ranging from 0 to 100, with higher scores indicating better QoL. Mean change from baseline=postbaseline value-baseline value; a higher value signifies improvement.
Time frame: At Day 169 from Baseline
Short-term Period: Number of Participants Achieving a Reduction of At Least 0.3 Unit From Baseline in HAQ-DI Scores at Day 169
The HAQ-DI assesses a participant's ability to perform the following tasks: dress/groom; arise; eat; walk; reach; grip; maintain hygiene; and maintain daily activity over a period by marking their response on a questionnaire. Responses/scores range from: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=to unable to do. Higher total score=greater disability.
Time frame: At Day 169 from Baseline
| Milestone | Abatacept 30/10 | Abatacept 10/10 | Abatacept 3/3 | Placebo |
|---|---|---|---|---|
| Started | 43 | 40 | 45 | 42 |
| Completed | 37 | 34 | 43 | 33 |
| Not completed | 6 | 6 | 2 | 9 |
| Withdrew: Adverse event | 1 | 2 | 1 | 3 |
| Withdrew: Lack of efficacy | 3 | 4 | 0 | 3 |
| Withdrew: Participant not meeting study criteria | 0 | 0 | 0 | 1 |
| Withdrew: Participant withdrew consent | 2 | 0 | 0 | 2 |
| Withdrew: Pregnancy | 0 | 0 | 1 | 0 |
| Milestone | Abatacept 30/10 | Abatacept 10/10 | Abatacept 3/3 | Placebo |
|---|---|---|---|---|
| Started | 37 | 34 | 43 | 33 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 37 | 34 | 43 | 33 |
| Withdrew: Adverse event | 2 | 1 | 0 | 1 |
| Withdrew: Lack of efficacy | 14 | 10 | 14 | 12 |
| Withdrew: Lost to follow-up | 1 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 2 | 0 | 0 |
| Withdrew: No longer meets study criteria | 0 | 1 | 0 | 0 |
| Withdrew: Poor compliance/noncompliance | 0 | 1 | 1 | 0 |
| Withdrew: Administrative reason by sponsor | 17 | 15 | 26 | 18 |
| Withdrew: Other | 1 | 2 | 2 | 2 |
Presp=prespecified; acute= ≤1 hour after start of infusion; periinfusional= ≤24 hours after start of infusion. AE=any new unfavorable symptom or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=an unfavorable medical event that at any dose results in death, significant disability, drug dependency/abuse, hospitalization or prolonged hospitalization; is life-threatening, an important medical event, or a congenital anomaly/birth defect. Drug-related=possibly, probably, or certainly related and of unknown relationship to study drug.
| Participants | All Treated Participants |
|---|---|
| Deaths | 0 |
| SAEs | 20 |
| Drug-related SAEs | 4 |
| SAEs leading to discontinuation | 0 |
| AEs | 123 |
| Drug-related AEs | 58 |
| AES leading to discontinuation | 4 |
| AEs of Interest (AEI): Infections | 83 |
| AEI: Malignancy | 2 |
| AEI: Autoimmune disorders (presp) | 5 |
| AEI: Infusion reactions (presp): Acute | 4 |
| AEI: Infusion reactions (presp): Periinfusional | 11 |
An ACR 20 (50, 70, 90) responder was a participant whose counts for both tender and swollen joints was reduced by 20% (50%, 70%, 90%, respectively) or more from baseline and who had a reduction of 20% (50%, 70%, 90%, respectively) or more from baseline in 3 of the following assessments: participant's assessment of disease activity, participant's global assessment of disease activity, Investigators Global Response, participant's assessment of physical function by Health Assessment Questionnaire Disability Index, and Disease Activity Score 28 based on C-reactive protein.
| Percentage of participants | Abatacept 30/10 | Abatacept 10/10 | Abatacept 3/3 | Placebo |
|---|---|---|---|---|
| ACR 20, Day 365 (n=34, 29, 36, 32) | 50.0 (33.2 to 66.8) | 62.1 (44.4 to 79.7) | 61.1 (45.2 to 77.0) | 46.9 (29.6 to 64.2) |
| ACR 20, Day 729 (n=21, 18, 26, 18) | 81 (64.2 to 97.7) | 66.7 (44.9 to 88.4) | 65.4 (47.1 to 83.7) | 72.2 (51.5 to 92.9) |
| ACR 50, Day 365 (n=34, 29, 36, 32) | 23.5 (9.3 to 37.8) | 37.9 (20.3 to 55.6) | 33.3 (17.9 to 48.7) | 34.4 (17.9 to 50.8) |
| ACR 50, Day 729 (n=21, 18, 26, 18) | 57.1 (36.0 to 78.3) | 27.8 (7.1 to 48.5) | 42.3 (23.3 to 61.3) | 55.6 (32.6 to 78.5) |
| ACR 70, Day 365 (n=34, 29, 36, 32) | 5.9 (0.0 to 13.8) | 17.2 (3.5 to 31.01) | 13.9 (2.6 to 25.2) | 18.8 (5.2 to 32.2) |
| ACR 70, Day 729 (n=21, 18, 26, 18) | 23.8 (5.6 to 42.0) | 16.7 (0.0 to 33.9) | 23.1 (6.9 to 39.3) | 11.1 (0.0 to 25.6) |
| ACR 90, Day 365 (n=34, 29, 36, 32) | 0 (0.0 to 0.0) | 6.9 (0.0 to 16.1) | 5.6 (0.0 to 13.0) | 6.3 (0.0 to 14.6) |
| ACR 90, Day 729 (n=21, 18, 26, 18) | 0 (0.0 to 0.0) | 5.6 (0.0 to 16.1) | 11.5 (0.0 to 23.8) | 0 (0.0 to 0.0) |
IGA score indicates lesion induration, scaling, and erythema: 0=clear (no signs of plaque psoriasis except for residual discoloration); 1=almost clear (just perceptible erythema, no induration to very slightly elevated above normal skin levels, limited amount of very fine scaling); 2=mild disease (mild erythema, mild induration, mainly fine scaling predominates); 3=moderate disease (moderate erythema \[most plaques are red\], moderate induration and/or coarse scale predominates); 4=severe (severe erythema, marked to very marked elevation of lesions, coarse thick scale predominates).
| Participants | Abatacept 30/10 | Abatacept 10/10 | Abatacept 3/3 | Placebo |
|---|---|---|---|---|
| Day 365 (n=30, 29, 34, 23) | 13 | 10 | 19 | 10 |
| Day 729 (n=20, 17, 26, 18) | 10 | 7 | 16 | 8 |
Target lesion score is a measurement of the degree of erythema, induration, and scale of a psoriatic lesion, at least 2 cm in diameter, selected as a target for response throughout the study period. The scores assigned were 0=clear, 1=almost clear, 2=mild clear, 3=moderate disease, 4=severe. Percent improvement from baseline was computed using the ratio of improvement from baseline to the baseline value.
| Percentage of change | Abatacept 30/10 | Abatacept 10/10 | Abatacept 3/3 | Placebo |
|---|---|---|---|---|
| Day 365 | 27.51 ± 7.92 | 41.97 ± 7.90 | 20.32 ± 8.59 | 33.82 ± 7.52 |
| Day 729 | 49.14 ± 9.13 | 45.07 ± 7.98 | 44.79 ± 9.09 | 34.41 ± 8.98 |
PCS=physical component score; MCS=mental component score. The SF-36 is a 36-item instrument with physical and mental components and covers quality of life (QoL) domains: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health. Responses are used to derive physical and mental component summary scores, ranging from 0 to 100, with higher scores indicating better QoL. Mean change from baseline=postbaseline value-baseline value; a higher value signifies improvement.
| Units on a scale | Abatacept 30/10 | Abatacept 10/10 | Abatacept 3/3 | Placebo |
|---|---|---|---|---|
| Day 365 PCS (n=34, 32, 37,29) | 1.73 ± 1.10 | 7.59 ± 1.36 | 4.86 ± 1.67 | 3.59 ± 1.19 |
| Day 365 MCS (n=34,32, 37,29) | 2.73 ± 1.60 | 1.07 ± 2.00 | 4.95 ± 2.10 | 4.40 ± 2.00 |
| Day 729 PCS (n=20,18, 26,18) | 5.59 ± 1.43 | 7.97 ± 2.0 | 6.74 ± 1.95 | 4.45 ± 1.14 |
| Day 729 MCS (n=20,18, 26,18) | 5.89 ± 1.84 | -0.17 ± 2.71 | 1.85 ± 2.11 | 4.35 ± 2.29 |
Per the HAQ-DI, participants assessed their own ability to perform the following tasks: dress/groom, arise, eat, walk, reach, grip, maintain hygiene, and maintain daily activity over a period by marking their responses on a questionnaire. Scoring of the HAQ-DI: 0=without any difficulty; 1=with some difficulty; 2=with much difficulty); and 3=unable to do. Greater score=greater disability. Responders with a \>= 0.3 unit decrease in index scores from baseline to days 365 and 729 were considered to be improved.
| Participants | Abatacept 30/10 | Abatacept 10/10 | Abatacept 3/3 | Placebo |
|---|---|---|---|---|
| Day 365 (n=3, 28, 32, 23) | 12 | 16 | 17 | 12 |
| Day 729 (n=9, 11, 13, 10) | 9 | 11 | 13 | 10 |
LLN=lower limit of normal; ULN=upper limit of normal; pre-Rx=pretreatment. Marked abnormalities are laboratory measurements marked as abnormal, per predefined study criteria, at any study time point. Criteria: Hemoglobin \>3 g/dL decrease from pre-Rx value; hematocrit \<0.75\*pre-Rx value; erythrocytes \<0.75\*pre-Rx value; platelets \<0.67\*LLN (or, if pre-Rx value \<LLN, \<0.5\*pre-Rx value and \<100000/mm\^3) or \>1.5\*ULN.
| Participants | Abatacept 30/10 | Abatacept 10/10 | Abatacept 3/3 | Placebo |
|---|---|---|---|---|
| Hemoglobin (n = 43, 40, 45, 41) | 0 | 0 | 0 | 0 |
| Hematocrit (n = 43, 40, 45, 41) | 0 | 0 | 0 | 0 |
| Erythrocytes (n = 43, 40, 45, 41) | 0 | 0 | 0 | 0 |
| Platelet count (n = 43, 40, 45, 41) | 0 | 0 | 0 | 0 |
An ACR 20 responder was a participant who had a reduction of 20% or more from baseline in scores for both tender and swollen joints and had a reduction from baseline of 20% or more in 3 out of the following 5 assessments: participant's assessment of disease activity, participant's global assessment of disease activity, investigator's global assessment of disease activity, participant's assessment of physical function by HAQ-DI, and Disease Activity Score 28-C reactive protein.
| Participants | Abatacept 30/10 | Abatacept 10/10 | Abatacept 3/3 | Placebo |
|---|---|---|---|---|
| Short-term Period: Number of Participants With ACR 20 Response at Day 169 | 18 | 19 | 15 | 8 |
LLN=lower limit of normal; ULN=upper limit of normal; pre-Rx=pretreatment. Laboratory measurements are marked as abnormal per predefined study criteria, at any study time point. Criteria for the data presented. Leukocytes \<0.75\*LLN or \>1.25\*ULN (or, if pre-Rx value \<LLN, \<0.8\*pre-Rx or \>ULN. If pre-Rx value \>ULN, \>1.2\*pre-Rx or \<LLN); neutrophils+bands (absolute) \<1.00\*10\^3 c/uL; lymphocytes (absolute) \<0.75\*10\^3 c/uL or \>7.50\*10\^3 c/uL; monocytes (absolute) \>2000/mm\^3; basophils (absolute) \>0.40\*10\^3 c/uL; eosinophils (absolute) \>0.75\*10\^3 c/uL.
| Participants | Abatacept 30/10 | Abatacept 10/10 | Abatacept 3/3 | Placebo |
|---|---|---|---|---|
| Leukocytes (n = 43, 40, 45, 41) | 0 | 0 | 2 | 0 |
| Neutrophils+bands (absolute) (n = 43, 40, 45, 41) | 0 | 0 | 0 | 0 |
| Lymphocytes (absolute) (n = 43, 40, 45, 41) | 2 | 0 | 6 | 1 |
| Monocytes (absolute) (n = 43, 40, 45, 41) | 0 | 0 | 0 | 0 |
| Basophils (absolute) (n = 43, 40, 45, 41) | 0 | 0 | 0 | 0 |
| Eosinophils (absolute) (n = 43, 40, 45, 41) | 1 | 1 | 1 | 0 |
ULN=upper limit of normal; pre-Rx=pretreatment. Marked abnormality criteria: Alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT) \>2\*ULN (if pre-Rx \>ULN, \>3\*pre-Rx); aspartate aminotransferase (AST), alanine transaminase (ALT) \>3\*ULN (if pre-Rx \>ULN, \>4\*pre-Rx); bilirubin (total) \>2\*ULN (if pre-Rx \>ULN, \>4\*pre-Rx); blood urea nitrogen (BUN) \>2\*pre-Rx; creatinine \>1.5\*pre-Rx.
| Participants | Abatacept 30/10 | Abatacept 10/10 | Abatacept 3/3 | Placebo |
|---|---|---|---|---|
| ALP (n = 43, 40, 45, 41) | 0 | 0 | 0 | 0 |
| AST (n = 43, 40, 45, 41) | 0 | 0 | 0 | 0 |
| ALT (n = 43, 40, 45, 41) | 1 | 0 | 0 | 0 |
| GGT (n = 43, 40, 45, 41) | 1 | 0 | 0 | 0 |
| Bilirubin (total) (n = 43, 40, 45, 41) | 0 | 0 | 0 | 0 |
| BUN (n = 43, 40, 45, 41) | 0 | 0 | 0 | 0 |
| Creatinine (n = 43, 40, 45, 41) | 0 | 0 | 0 | 0 |
LLN=lower limit of normal; ULN=upper limit of normal; pre-Rx=pretreatment. Marked abnormality criteria: Sodium \<0.95\*LLN or \>1.05\*ULN (if pre-Rx\<LLN, \<0.95\*pre-Rx or \>ULN. If pre-Rx \>ULN,\>1.05\* pre-Rx or \<LLN); potassium, chloride \<0.9\*LLN or \>1.1\*ULN (if pre-Rx \<LLN, \<0.9\*pre-Rx or \>ULN. If pre-Rx \>ULN, \>1.1\*pre-Rx or \<LLN); calcium \<0.8\*LLN or \>1.2\*ULN (if pre-Rx \<LLN,\<0.75\* pre-Rx or \>ULN. If pre-Rx \>ULN, \>1.25\* pre-Rx or \<LLN); phosphorous \<0.75\*LLN or \>1.25\*ULN (if pre-Rx \<LLN, \<0.67\*pre-Rx or \>ULN. If pre-Rx \>ULN, \>1.33\*pre-Rx or \<LLN.
| Participants | Abatacept 30/10 | Abatacept 10/10 | Abatacept 3/3 | Placebo |
|---|---|---|---|---|
| Sodium (n = 43, 40, 45, 41) | 0 | 0 | 0 | 0 |
| Potassium (n = 43, 40, 45, 41) | 0 | 0 | 0 | 1 |
| Chloride (n = 43, 40, 45, 41) | 0 | 0 | 0 | 0 |
| Calcium (total) (n = 43, 40, 45, 41) | 0 | 0 | 0 | 0 |
| Phosphorous , inorganic (n = 43, 40, 45, 41) | 0 | 0 | 1 | 1 |
LLN=lower limit of normal; ULN=upper limit of normal; pre-Rx=pretreatment. Marked abnormality criteria: Glucose \<65 or \>220 mg/dL; glucose (fasting)\<0.8\*LLN or \>1.5\*ULN (if pre-Rx \<LLN, \<0.8\*pre-Rx or \>ULN. If pre-Rx \>ULN, t\>2.0\*pre-Rx or \<LLN). Protein (total) \<0.9\*LLN or \>1.1\*ULN (if pre-Rx \<LLN, \<0.9\*pre-Rx or \>ULN. If pre-Rx \>ULN, \>1.1\*pre-Rx or \<LLN). Albumin \<0.9\*LLN (if pre-Rx \<LLN, \<0.75\* pre-Rx). Uric acid \>1.5\*ULN; if pre-Rx \>ULN or \>2\*pre-Rx value.
| Participants | Abatacept 30/10 | Abatacept 10/10 | Abatacept 3/3 | Placebo |
|---|---|---|---|---|
| Glucose (n = 43, 40, 45, 41) | 1 | 4 | 8 | 2 |
| Glucose, fasting (n = 16, 12, 12, 15) | 0 | 0 | 0 | 0 |
| Protein (total) (n = 43, 40, 45, 41) | 0 | 0 | 0 | 0 |
| Albumin (n = 43, 40, 45, 41) | 0 | 0 | 0 | 0 |
| Uric acid (n = 43, 40, 45, 41) | 0 | 0 | 0 | 0 |
Pre-Rx=pretreatment. Criteria for marked abnormality: Protein, glucose, blood, leukocyte esterase, red blood cells (RBC), white blood cells (WBC) \>=2+ (or, if value \>=4, or if pre-Rx value=0 or 0.5, \>= 2\* or if pre-RX value =1, \>=3, or if pre-Rx =2 or 3, \>=4).
| Participants | Abatacept 30/10 | Abatacept 10/10 | Abatacept 3/3 | Placebo |
|---|---|---|---|---|
| Protein (n = 42, 37, 38, 40) | 0 | 0 | 0 | 1 |
| Glucose (n = 42, 37, 38, 40) | 0 | 0 | 0 | 1 |
| Blood (n = 42, 37, 38, 40) | 2 | 2 | 3 | 2 |
| Leukocyte esterase (n = 3, 7, 4, 5) | 0 | 0 | 1 | 1 |
| WBC (n = 6, 8, 8, 6) | 1 | 1 | 3 | 3 |
| RBC (n = 6, 7, 5, 6) | 3 | 1 | 1 | 2 |
An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Drug-related=possibly, probably, or certainly related to and of unknown relationship to study treatment.
| Participants | Abatacept 30/10 | Abatacept 10/10 | Abatacept 3/3 | Placebo |
|---|---|---|---|---|
| Deaths | 0 | 0 | 0 | 0 |
| SAEs | 4 | 2 | 0 | 1 |
| AEs | 29 | 31 | 31 | 30 |
| All AEs Leading to Discontinuation | 1 | 2 | 1 | 3 |
| All SAEs Leading to Discontinuation | 1 | 0 | 0 | 0 |
| Drug-related AEs | 13 | 13 | 12 | 7 |
| Drug-related SAEs | 1 | 1 | 0 | 0 |
Score indicates lesion induration, scaling, and erythema: 0 = clear (no signs of plaque psoriasis except for residual discoloration); 1 = almost clear (just perceptible erythema, no induration to very slightly elevated above normal skin levels, limited amount of very fine scaling); 2 = mild disease (mild erythema, mild induration, mainly fine scaling predominates); 3 = moderate disease (moderate erythema \[most plaques are red\], moderate induration and/or coarse scale predominates); 4=severe (severe erythema, marked to very marked elevation of lesions, coarse thick scale predominates).
| Participants | Abatacept 30/10 | Abatacept 10/10 | Abatacept 3/3 | Placebo |
|---|---|---|---|---|
| Short-term Period: Number of Participants With an IGA Score of Clear or Almost Clear at Day 169 | 9 | 10 | 17 | 11 |
Target lesion score measures the degree of erythema, induration, and scale of a psoriatic lesion with a diameter of at least 2 cm, selected as a target for response throughout the study period. Scores: 0=clear, 1=almost clear, 2=mild clear, 3=moderate disease, 4=severe. Percent improvement from baseline was computed using the ratio of improvement from baseline to the baseline value.
| Percentage of change | Abatacept 30/10 | Abatacept 10/10 | Abatacept 3/3 | Placebo |
|---|---|---|---|---|
| Short-term Period: Mean Percentage of Change From Baseline in Target Lesion Score at Day 169 | 19.39 ± 9.16 | 22.96 ± 9.46 | 31.11 ± 8.98 | 0.63 ± 9.35 |
Meso Scale Discovery electrochemiluminescence, a validated, sensitive immunoassay technique (anti-abatacept assay C) was used to measure serum levels of abatacept-specific antibodies against the whole molecule (both the CTLA4 and possibly immunoglobulin G portion \[anti-abatacept antibody\].
| Participants | Abatacept 30/10 | Abatacept 10/10 | Abatacept 3/3 |
|---|---|---|---|
| Short-term Period: Number of Participants With Positive Responses for Serum Levels of Abatacept-specific Antibodies (Anti-Abatacept-C) | 1 | 0 | 2 |
PCS=physical component score; MCS=mental component score. The Short-form 36 is a 36-item instrument with physical and mental components and covers quality of life (QoL) domains: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health. Responses are used to derive physical and mental component summary scores, ranging from 0 to 100, with higher scores indicating better QoL. Mean change from baseline=postbaseline value-baseline value; a higher value signifies improvement.
| Units on a scale | Abatacept 30/10 | Abatacept 10/10 | Abatacept 3/3 | Placebo |
|---|---|---|---|---|
| Short-term Period: Mean Change From Baseline in the Mental Component Summary Score as Measured by the Short-form 36 at Day 169 | 4.50 ± 2.45 | 4.42 ± 2.50 | 3.16 ± 2.41 | 2.41 ± 2.47 |
Abatacept was assayed using a validated enzyme linked immunosorbent assay method (ELISA). Serum concentration versus time data was analyzed in the descriptive pharmacokinetic (PK) analysis.
| µg/mL | Abatacept 30/10 | Abatacept 10/10 | Abatacept 3/3 |
|---|---|---|---|
| Day 1 (n= 13, 13, 44) | 0 ± 0 | 0.01 ± 0.01 | 0 ± 0 |
| Day 15 (n= 43, 38, 42) | 119.99 ± 35.30 | 48.29 ± 17.96 | 14.28 ± 7.67 |
| Day 29 (n= 41, 39, 43) | 186.82 ± 62.49 | 49.70 ± 16.79 | 16.20 ± 4.86 |
| Day 57 (n= 40, 39, 44) | 58.55 ± 26.09 | 25.75 ± 9.67 | 10.42 ± 5.75 |
| Day 85 (n= 37, 35, 41) | 39.00 ± 19.37 | 26.29 ± 10.59 | 8.73 ± 3.26 |
| Day 113 ( n= 35, 33, 43) | 36.30 ± 19.94 | 32.69 ± 14.08 | 8.85 ± 5.01 |
| Day 141 (n= 35, 34, 42) | 26.70 ± 9.24 | 25.78 ± 9.74 | 7.66 ± 3.13 |
| Day 169 (n= 36, 42, 34) | 28.93 ± 11.29 | 26.34 ± 10.75 | 9.29 ± 5.23 |
Abatacept was assayed using a validated ELISA method. Cmin of abatacept was obtained from concentration versus time data.
| µg/mL | Abatacept 30/10 | Abatacept 10/10 | Abatacept 3/3 |
|---|---|---|---|
| Day 15 (n= 43, 38, 43) | 115.35 (70.65 to 236.39) | 45.10 (21.27 to 95.96) | 12.81 (4.25 to 39.81) |
| Day 29 (n= 41, 39, 43) | 176.22 (68.45 to 373.07) | 46.86 (21.23 to 87.55) | 15.43 (4.99 to 28.15) |
| Day 57 (n= 40, 39, 44) | 53.08 (11.21 to 151.10) | 23.88 (8.18 to 50.84) | 9.03 (2.53 to 33.88) |
| Day 85 (n= 37, 35, 41) | 33.09 (1.87 to 94.46) | 24.36 (10.47 to 55.13) | 8.15 (2.97 to 16.01) |
| Day 113 (n= 35, 33, 43) | 31.50 (8.30 to 78.91) | 29.60 (6.66 to 71.21) | 7.56 (2.14 to 27.82) |
| Day 141 (n= 35, 34, 42) | 25.02 (10.77 to 43.31) | 23.62 (7.24 to 45.66) | 6.91 (1.50 to 14.32) |
| Day 169 (n= 36, 34, 42) | 26.65 (10.05 to 53.77) | 24.33 (11.65 to 50.31) | 7.84 (1.68 to 28.85) |
PK data: summaries of concentrations and concentration versus time plots were obtained. These data were to be used to develop a POPPK model using a nonlinear mixed-effects model. Prediction of PK data for each of the 3 abatacept treatment groups using POPPK methodology was not performed, because it would not provide any relevant information over the observed PK data.
No measurements were reported for this outcome.
PCS=physical component score; MCS=mental component score. The Short-form 36 is a 36-item instrument with physical and mental components and covers quality of life (QoL) domains: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health. Responses are used to derive physical and mental component summary scores, ranging from 0 to 100, with higher scores indicating better QoL. Mean change from baseline=postbaseline value-baseline value; a higher value signifies improvement.
| Units on a scale | Abatacept 30/10 | Abatacept 10/10 | Abatacept 3/3 | Placebo |
|---|---|---|---|---|
| Short-term Period: Mean Change From Baseline in Physical Component Summary Score as Measured by the Short-form 36 at Day 169 | 7.30 ± 1.85 | 9.27 ± 1.91 | 6.32 ± 1.82 | 0.15 ± 1.87 |
The HAQ-DI assesses a participant's ability to perform the following tasks: dress/groom; arise; eat; walk; reach; grip; maintain hygiene; and maintain daily activity over a period by marking their response on a questionnaire. Responses/scores range from: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=to unable to do. Higher total score=greater disability.
| Participants | Abatacept 30/10 | Abatacept 10/10 | Abatacept 3/3 | Placebo |
|---|---|---|---|---|
| Short-term Period: Number of Participants Achieving a Reduction of At Least 0.3 Unit From Baseline in HAQ-DI Scores at Day 169 | 15 | 18 | 16 | 8 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abatacept 10/10 (Short-term Period) | — | 2/40 (5%) | 16/40 (40%) |
| Abatacept 3/3 (Short-term Period) | — | 1/45 (2.2%) | 15/45 (33.3%) |
| Abatacept 30/10 (Short-term Period) | — | 4/43 (9.3%) | 16/43 (37.2%) |
| Abatacept (Long-term Period) | — | 20/147 (13.6%) | 73/147 (49.7%) |
| Placebo (Short-term Period) | — | 1/42 (2.4%) | 19/42 (45.2%) |
| Event | Abatacept 10/10 (Short-term Period) | Abatacept 3/3 (Short-term Period) | Abatacept 30/10 (Short-term Period) | Abatacept (Long-term Period) | Placebo (Short-term Period) |
|---|---|---|---|---|---|
| GastroenteritisInfections and infestations | 1/40 | 0/45 | 0/43 | 1/147 | 0/42 |
| DizzinessNervous system disorders | 1/40 | 0/45 | 0/43 | 0/147 | 0/42 |
| Personality disorderPsychiatric disorders | 0/40 | 0/45 | 0/43 | 1/147 | 1/42 |
| Family stressSocial circumstances | 0/40 | 0/45 | 0/43 | 1/147 | 1/42 |
| Cholecystitis acuteHepatobiliary disorders | 0/40 | 0/45 | 1/43 | 0/147 | 0/42 |
| OsteomyelitisInfections and infestations | 0/40 | 0/45 | 1/43 | 0/147 | 0/42 |
| OverdoseInjury, poisoning and procedural complications | 0/40 | 0/45 | 1/43 | 0/147 | 0/42 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/40 | 0/45 | 1/43 | 0/147 | 0/42 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/40 | 1/45 | 0/43 | 3/147 | 0/42 |
| Psoriatic arthropathyMusculoskeletal and connective tissue disorders | 0/40 | 1/45 | 0/43 | 0/147 | 0/42 |
| Event | Abatacept 10/10 (Short-term Period) | Abatacept 3/3 (Short-term Period) | Abatacept 30/10 (Short-term Period) | Abatacept (Long-term Period) | Placebo (Short-term Period) |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 4/40 | 5/45 | 4/43 | 33/147 | 4/42 |
| Upper respiratory tract infectionInfections and infestations | 1/40 | 3/45 | 2/43 | 16/147 | 2/42 |
| HeadacheNervous system disorders | 1/40 | 3/45 | 4/43 | 9/147 | 4/42 |
| BronchitisInfections and infestations | 1/40 | 0/45 | 3/43 | 13/147 | 1/42 |
| SinusitisInfections and infestations | 2/40 | 1/45 | 2/43 | 12/147 | 2/42 |
| DiarrhoeaGastrointestinal disorders | 3/40 | 0/45 | 0/43 | 8/147 | 2/42 |
| FatigueGeneral disorders | 3/40 | 1/45 | 1/43 | 3/147 | 1/42 |
| HypertensionVascular disorders | 3/40 | 1/45 | 1/43 | 7/147 | 1/42 |
| NauseaGastrointestinal disorders | 2/40 | 1/45 | 2/43 | 6/147 | 3/42 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/40 | 1/45 | 3/43 | 8/147 | 1/42 |
| Age Continuous(years) | Abatacept 30/10 | Abatacept 10/10 | Abatacept 3/3 | Placebo | Total |
|---|---|---|---|---|---|
| Median | 54.0 (29.0 to 69.0) | 51.5 (26.0 to 73.0) | 51.0 (29.0 to 72.0) | 53.0 (30.0 to 82.0) | 52.0 (26.0 to 82.0) |
| Sex: Female, Male(Participants) | Abatacept 30/10 | Abatacept 10/10 | Abatacept 3/3 | Placebo | Total |
|---|---|---|---|---|---|
| Female | 23 | 14 | 23 | 19 | 79 |
| Male | 20 | 26 | 22 | 23 | 91 |
| Race/Ethnicity, Customized(participants) | Abatacept 30/10 | Abatacept 10/10 | Abatacept 3/3 | Placebo | Total |
|---|---|---|---|---|---|
| White | 43 | 38 | 44 | 41 | 166 |
| Asian | 0 | 2 | 1 | 0 | 3 |
| Pacific | 0 | 0 | 0 | 1 | 1 |
| Weight(kilograms) | Abatacept 30/10 | Abatacept 10/10 | Abatacept 3/3 | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 92.9 ± 21.3 | 85.0 ± 17.9 | 85.0 ± 19.1 | 96.0 ± 19.4 | 89.7 ± 19.9 |
The record gives a start of Nov 2007, a primary completion of Dec 2008 and a completion of May 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2010, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept